REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/Highlighting the efficacy and importance of continued GLP-1 receptor agonist therapy, specifically semaglutide, in maintaining weight loss for patients with obesity or overweight.
Back to Research Library
semaglutideGLP-1 receptor agonist

Highlighting the efficacy and importance of continued GLP-1 receptor agonist therapy, specifically semaglutide, in maintaining weight loss for patients with obesity or overweight.

May 17, 2026
Share

Source Paper

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.

Rubino Domenica et al.JAMA2021
Emerging Research

Based on emerging research. These findings are promising but require further validation.

About This Analysis

This article breaks down the findings from the source paper above into accessible language for the peptide research community. Our goal is to highlight what matters most — the practical implications, the strength of the evidence, and what it means for ongoing research.

Maintaining Weight Loss with Semaglutide: A New Hope for Obesity Management

Published: May 17, 2026 | Source: JAMA (2021) | Category: semaglutide, GLP-1 receptor agonist

Overview

A recent study published in the Journal of the American Medical Association (JAMA) highlights the efficacy of continued weekly subcutaneous semaglutide treatment for maintaining weight loss in adults with overweight or obesity. This research underscores the importance of sustained therapy using glucagon-like peptide 1 (GLP-1) receptor agonists like semaglutide to achieve long-term health benefits.

Study Background

Before this study, it was unclear whether continuing GLP-1 receptor agonist treatment after initial weight loss would be necessary for maintaining those results. Previous research had shown that these medications are effective in inducing significant weight loss, but questions remained about the optimal duration of therapy and whether patients could maintain their weight without continued medication.

What the Research Found

The STEP 4 randomized clinical trial involved 803 participants who initially received semaglutide for a 20-week period. After reaching a maintenance dose, these individuals were randomly assigned to either continue with semaglutide or switch to placebo for an additional 48 weeks. The primary outcome was the percentage change in body weight from week 20 to week 68.

The results showed that participants who continued taking semaglutide maintained their weight loss, experiencing a further reduction of -7.9% on average compared to those who switched to placebo, whose weight increased by +6.9%. Additionally, the study observed significant improvements in waist circumference and systolic blood pressure among those continuing with semaglutide.

What This Means for Peptide Users

For individuals using GLP-1 receptor agonists like semaglutide for weight management, this research suggests that discontinuing treatment may lead to rapid weight regain. Therefore, patients should consider the long-term benefits of sustained therapy and discuss continuation plans with their healthcare providers to ensure continued health improvements.

Limitations and Caveats

While the study provides valuable insights into the role of semaglutide in maintaining weight loss, it has several limitations. The relatively short follow-up period of 68 weeks may not be sufficient to assess long-term efficacy and safety. Additionally, participants with diabetes were excluded from this trial, which limits its applicability to a broader population.

How This Compares to Previous Research

Previous studies have also highlighted the effectiveness of GLP-1 receptor agonists in inducing weight loss but often did not address maintenance strategies beyond initial treatment phases. The STEP 4 study is unique in directly comparing continued therapy with discontinuation, providing clearer guidance on long-term management strategies.

Our Analysis

PeptideVault views this research as a significant step forward in understanding the role of GLP-1 receptor agonists like semaglutide for weight loss maintenance. However, it is crucial to acknowledge that further studies are needed to confirm these findings over longer periods and across diverse patient populations, including those with diabetes.

Key Takeaways

  • Sustained Therapy: Continued use of semaglutide can help maintain significant weight loss achieved during initial treatment phases.
  • Health Benefits: Beyond weight management, the study indicates additional health benefits such as improved waist circumference and blood pressure control.
  • Further Research Needed: Longer-term studies are essential to fully understand the long-term efficacy and safety of GLP-1 receptor agonists.

Original Source

Citation: Rubino Domenica, Abrahamsson Niclas, Davies Melanie et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.. JAMA. DOI: 10.1001/jama.2021.3224

Access: https://pubmed.ncbi.nlm.nih.gov/33755728/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was prepared by the Peptide Contacts research team. We encourage readers to review the full source paper for complete methodology and data. The original publication is available on PubMed.

Related Research

Highlighting the potential of tirzepatide as a novel dual GIP and GLP-1 receptor agonist for managing type 2 diabetes, focusing on its efficacy and safety profile.

tirzepatideGIP receptor agonistGLP-1 receptor agonist

Highlighting the differential risk profiles of various GLP-1 receptor agonists for gastrointestinal adverse events based on real-world data, emphasizing implications for clinical practice.

GLP-1 receptor agonistsexenatideliraglutide

Highlighting the comparative effectiveness and patient outcomes between once-weekly semaglutide and daily liraglutide for weight management in non-diabetic obese patients.

semaglutideliraglutide

Comments

Sign in to join the discussion

This analysis is generated from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.